---
title: "BIO GREEN MED SOLUTION INC. 6% CNV PFD USD | 10-Q: FY2025 Q3 Revenue: USD 81 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265800433.md"
datetime: "2025-11-13T22:20:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265800433.md)
  - [en](https://longbridge.com/en/news/265800433.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265800433.md)
generator: "portal-rs"
---

# BIO GREEN MED SOLUTION INC. 6% CNV PFD USD | 10-Q: FY2025 Q3 Revenue: USD 81 K

Revenue: As of FY2025 Q3, the actual value is USD 81 K.

EPS: As of FY2025 Q3, the actual value is USD -1.31.

EBIT: As of FY2025 Q3, the actual value is USD -1.001 M.

### Segment Revenue

-   **Product Revenue - Fire Safety**: $81,000 for the three and nine months ended September 30, 2025.
-   **Clinical Trial Supply**: $0 for the three and nine months ended September 30, 2025, compared to $10,000 and $43,000 for the same periods in 2024.

### Operational Metrics

-   **Operating Loss**: - $992,000 for the three months ended September 30, 2025, compared to - $2,177,000 for the same period in 2024.
-   **Net Loss**: - $988,000 for the three months ended September 30, 2025, compared to - $1,957,000 for the same period in 2024.
-   **Total Operating Expenses**: $1,073,000 for the three months ended September 30, 2025, compared to $2,187,000 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $4,737,000 for the nine months ended September 30, 2025, compared to - $6,634,000 for the same period in 2024.
-   **Net Cash Provided by Financing Activities**: $5,523,000 for the nine months ended September 30, 2025, compared to $6,209,000 for the same period in 2024.

### Unique Metrics

-   **Gain on Deconsolidation of Subsidiary**: $4,947,000 for the nine months ended September 30, 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to focus on fire safety protection and distribution activities following the acquisition of Fitters Sdn. Bhd., anticipating growth in revenues during the fourth quarter of 2025.
-   **Non-Core Business**: The company sold its bio-pharmaceutical asset plogosertib for $300,000, with a potential milestone payment of $170,000.
-   **Priority**: The company is exploring strategic alternatives to continue as a going concern, including raising additional capital through equity financing or strategic transactions.

### Related Stocks

- [BGMSP.US](https://longbridge.com/en/quote/BGMSP.US.md)

## Related News & Research

- [How Foot Locker went from a sneakerhead destination to a store struggling to get rid of old shoes](https://longbridge.com/en/news/297208698.md)
- [Nvidia Revenue Set to Increase 18X in 4 Years; Analyst Says 'Never in History' Has a Company Grown This Fast](https://longbridge.com/en/news/297126014.md)
- [Alphabet Is a 'Top 2027 Stock Pick,' Says Wolfe Research Analyst. Here's Why](https://longbridge.com/en/news/297186957.md)
- [Zhongji Innolight Fully Exercises Over-Allotment Option After Hong Kong IPO](https://longbridge.com/en/news/297095479.md)
- [Broadcom Stock (AVGO) Remains Wall Street's Pick Despite Google's Marvell Deal – Here's Why](https://longbridge.com/en/news/297093302.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**